Axa decreased its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 3.3% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 171,049 shares of the pharmaceutical company’s stock after selling 5,880 shares during the period. Axa owned about 0.07% of Vertex Pharmaceuticals worth $22,043,000 at the end of the most recent quarter.
Other large investors have also added to or reduced their stakes in the company. Private Advisor Group LLC raised its stake in Vertex Pharmaceuticals by 1.8% in the first quarter. Private Advisor Group LLC now owns 5,328 shares of the pharmaceutical company’s stock valued at $607,000 after buying an additional 94 shares during the period. Teachers Advisors LLC increased its stake in shares of Vertex Pharmaceuticals by 48.6% during the first quarter. Teachers Advisors LLC now owns 510,373 shares of the pharmaceutical company’s stock worth $55,809,000 after purchasing an additional 166,998 shares during the period. Dynamic Capital Management Ltd increased its stake in shares of Vertex Pharmaceuticals by 53.8% during the first quarter. Dynamic Capital Management Ltd now owns 39,614 shares of the pharmaceutical company’s stock worth $4,332,000 after purchasing an additional 13,853 shares during the period. Neuberger Berman Group LLC increased its stake in shares of Vertex Pharmaceuticals by 5.1% during the first quarter. Neuberger Berman Group LLC now owns 246,331 shares of the pharmaceutical company’s stock worth $26,936,000 after purchasing an additional 12,060 shares during the period. Finally, Westfield Capital Management Co. LP bought a new position in shares of Vertex Pharmaceuticals during the first quarter worth approximately $38,915,000. Hedge funds and other institutional investors own 92.88% of the company’s stock.
Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) opened at 158.83 on Friday. The company’s 50 day moving average price is $155.51 and its 200 day moving average price is $124.66. Vertex Pharmaceuticals Incorporated has a 12-month low of $71.46 and a 12-month high of $167.86. The firm has a market cap of $40.04 billion, a P/E ratio of 152.57 and a beta of 1.75.
Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.33. Vertex Pharmaceuticals had a net margin of 12.05% and a return on equity of 4.64%. The company had revenue of $544.10 million during the quarter, compared to analyst estimates of $489.95 million. During the same period in the previous year, the business earned $0.24 earnings per share. The firm’s quarterly revenue was up 26.1% compared to the same quarter last year. Equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post $1.60 EPS for the current year.
In related news, CMO Jeffrey Chodakewitz sold 3,438 shares of the company’s stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $127.80, for a total value of $439,376.40. Following the completion of the transaction, the chief marketing officer now directly owns 125,949 shares in the company, valued at $16,096,282.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Paul M. Silva sold 2,577 shares of the company’s stock in a transaction on Wednesday, June 21st. The stock was sold at an average price of $133.36, for a total transaction of $343,668.72. Following the completion of the transaction, the senior vice president now owns 22,648 shares of the company’s stock, valued at $3,020,337.28. The disclosure for this sale can be found here. Insiders sold 526,092 shares of company stock valued at $84,101,702 over the last quarter. 1.80% of the stock is owned by company insiders.
A number of equities analysts have recently weighed in on the company. Maxim Group set a $195.00 target price on Vertex Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, July 27th. J P Morgan Chase & Co set a $184.00 target price on Vertex Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, July 27th. Oppenheimer Holdings, Inc. increased their target price on Vertex Pharmaceuticals from $150.00 to $175.00 and gave the stock an “outperform” rating in a research note on Thursday, July 27th. Morgan Stanley reiterated an “overweight” rating and set a $190.00 target price (up previously from $153.00) on shares of Vertex Pharmaceuticals in a research note on Saturday, July 22nd. Finally, Vetr lowered Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $181.00 target price on the stock. in a research note on Monday, July 24th. Six analysts have rated the stock with a hold rating and twenty-two have given a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $162.88.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).
Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.